Delaware | ||||
(State or other jurisdiction of incorporation) | ||||
001-37590 | 45-0705648 | |||
(Commission File Number) | (IRS Employer Identification No.) |
540 Gaither Road, Suite 400, Rockville, Maryland 20850 (Address of principal executive offices) (Zip Code) | ||
Registrant’s Telephone Number, Including Area Code: (410) 522-8707 |
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, $0.001 Par Value | CERC | Nasdaq Capital Market |
Exhibit No. | Description | |
99.1 | ||
CERECOR INC. | |||
Date: May 7, 2020 | /s/ Christopher Sullivan | ||
Christopher Sullivan | |||
Interim Chief Financial Officer |
• | Initiated biomarker study to evaluate the role of LIGHT in the development of Acute Respiratory Distress Syndrome (“ARDS”) and Acute Lung Injury (“ALI”) in hospitalized COVID-19 patients |
• | Dr. Sol Barer joined Board of Directors and was appointed Chairman of the Board |
• | Appointed Dr. Suzanne Bruhn and Mr. Joseph Miller to the Board |
• | Closed merger with Aevi Genomic Medicine, increasing pipeline to six clinical assets |
March 31, 2020 (a) | December 31, 2019 (a) | |||||||
(unaudited) | ||||||||
(in thousands) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 5,659 | $ | 3,609 | ||||
Accounts receivable, net | 2,195 | 1,002 | ||||||
Other receivables | 2,064 | 4,241 | ||||||
Inventory, net | 16 | 21 | ||||||
Prepaid expenses and other current assets | 777 | 707 | ||||||
Restricted cash, current portion | 65 | 17 | ||||||
Investment in Aytu | 14,709 | 7,629 | ||||||
Current assets of discontinued operations | — | 498 | ||||||
Total current assets | 25,485 | 17,724 | ||||||
Property and equipment, net | 1,417 | 1,448 | ||||||
Intangible assets, net | 2,696 | 2,426 | ||||||
Goodwill | 14,409 | 14,409 | ||||||
Restricted cash, net of current portion | 113 | 102 | ||||||
Total assets | $ | 44,120 | $ | 36,109 | ||||
Liabilities and stockholders’ equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 2,726 | $ | 2,078 | ||||
Accrued expenses and other current liabilities | 6,194 | 5,640 | ||||||
Income taxes payable | — | 552 | ||||||
Current liabilities of discontinued operations | 6,410 | 3,891 | ||||||
Total current liabilities | 15,330 | 12,161 | ||||||
Royalty obligation | 2,000 | — | ||||||
Deferred tax liability, net | 107 | 86 | ||||||
Other long-term liabilities | 1,094 | 1,112 | ||||||
Long-term liabilities of discontinued operations | — | 1,755 | ||||||
Total liabilities | 18,531 | 15,114 | ||||||
Stockholders’ equity: | ||||||||
Common stock—$0.001 par value; 200,000,000 shares authorized at March 31, 2020 and December 31, 2019; 59,560,252 and 44,384,222 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively | 60 | 44 | ||||||
Preferred stock—$0.001 par value; 5,000,000 shares authorized at March 31, 2020 and December 31, 2019; 1,257,143 and 2,857,143 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively | 1 | 3 | ||||||
Additional paid-in capital | 160,936 | 135,239 | ||||||
Accumulated deficit | (135,408 | ) | (114,291 | ) | ||||
Total stockholders’ equity | 25,589 | 20,995 | ||||||
Total liabilities and stockholders’ equity | $ | 44,120 | $ | 36,109 | ||||
(a) The condensed consolidated balance sheets as of March 31, 2020 and December 31, 2019 have been derived from the reviewed and audited financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. |
Three Months Ended | ||||||||
March 31, | ||||||||
2020 (a) | 2019 (a) | |||||||
(in thousands, except per share data) | ||||||||
Revenues: | ||||||||
Product revenue, net | $ | 2,754 | $ | 2,576 | ||||
Total revenues, net | 2,754 | 2,576 | ||||||
Operating expenses: | ||||||||
Cost of product sales | 66 | 752 | ||||||
Research and development | 4,768 | 3,401 | ||||||
Acquired in-process research and development | 25,549 | — | ||||||
General and administrative | 2,676 | 2,676 | ||||||
Sales and marketing | 677 | 396 | ||||||
Amortization expense | 431 | 335 | ||||||
Change in fair value of contingent consideration | — | 21 | ||||||
Total operating expenses | 34,167 | 7,581 | ||||||
Loss from continuing operations | (31,413 | ) | (5,005 | ) | ||||
Other income (expense): | ||||||||
Change in fair value of Investment in Aytu | 7,080 | — | ||||||
Change in fair value of warrant liability and unit purchase option liability | 11 | (48 | ) | |||||
Other expense, net | — | (9 | ) | |||||
Interest income, net | 10 | 30 | ||||||
Total other income (expense), net from continuing operations | 7,101 | (27 | ) | |||||
Loss from continuing operations before taxes | (24,312 | ) | (5,032 | ) | ||||
Income tax (benefit) expense | (2,157 | ) | 130 | |||||
Loss from continuing operations | $ | (22,155 | ) | $ | (5,162 | ) | ||
Income (loss) from discontinued operations, net of tax | 1,038 | (2,292 | ) | |||||
Net loss | $ | (21,117 | ) | $ | (7,454 | ) | ||
Net (loss) income per share of common stock, basic and diluted: | ||||||||
Continuing operations | $ | (0.36 | ) | $ | (0.09 | ) | ||
Discontinued operations | 0.02 | (0.04 | ) | |||||
Net loss per share of common stock, basic and diluted | $ | (0.34 | ) | $ | (0.13 | ) | ||
Net (loss) income per share of preferred stock, basic and diluted: | ||||||||
Continuing operations | $ | (1.78 | ) | $ | (0.46 | ) | ||
Discontinued operations | 0.08 | (0.21 | ) | |||||
Net loss per share of preferred stock, basic and diluted | $ | (1.70 | ) | $ | (0.67 | ) | ||
(a) The unaudited condensed consolidated statements of operations for the three months ended March 31, 2020 and 2019 have been derived from the reviewed financial statements but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. |
• | CERC-800s (CERC-801, CERC-802 and CERC-803) anticipate initial data readout from the CDG-FIRST Trial within the 1st Half of 2020 |
• | CERC-002 (anti-LIGHT mAb) being developed for Pediatric-onset Crohn’s Disease expects initial data readout in Q1 2021 with the moratorium placed on endoscopy from the AGA |
• | CERC-007 (anti-IL-18 mAb) being developed for auto-inflammatory diseases (AOSD, MM) expects initial data readout in Q4 2020 to Q1 2021 |
• | CERC-006 (dual mTOR inhibitor) being developed for complex Lymphatic Malformations anticipates initial data readout within the 1st Half 2021 |
:5HNH:]=+:Z;876HW+<+#:PM*Y^@4$UUTOP'^ M)4-N)W^'WBA82,[SH]QC'_?%?L5X'^'/AGX;:/#IGAK1;/2+2-0NVWB 9_=V M^\Q]R23725G[7LC3V?F?B5\/_A9K/CCXEZ'X-:UN-.O]1NU@?[1"R-"F@ &235Z;2+&XU" MWOI;.WDO;<,(;EXE,D>1@[6QD9''%?%/_!1KX[3Z/I]E\-='NO+EOHQ=ZNT9 M^80Y_=PD]MQ&XCK@+V;F6W4:0TE35SQ[]JO]M+6/BQJ%YX<\)74VD^#(WV&6 M(F.?4"L9[)WP"WH/EE5+, !DG@ 4Z&&2XF2*)&DE=@J(@)9B> .YK] M0/V2_P!CG2/A7H=GXC\5V$.H^,[J,2>5 HC4N[,J5.RNCXC_9V^/6L_ 7Q[:ZM92O+I$[K%J>GDG9/#D9(' M9U'*MZ\="17[$Z/JUIKVDV6I6$RW-C>0I<03( Y>,= $=;UB9ML M6GV,]V[>@CC9C_*OPVOKR34+ZXNI3F6>1I7/NQ)/\Z_67]N7Q8WA3]FWQ,(I M/+GU(Q:K>'Y FJZ7>Z:[=%O+=XB?P8"OUS_9!\%_\ ""_LZ^#+)UVW%U:? MVC-Z[IV,H!]PK*O_ &O1O&W@?0_B)X 3/AKJ%E/ENV>KC8P)[X!ZDU^;WC[PV/!OCC7]"60S+IM_- M:+(>K!'*@G\!6;IVLWVD^9]BNI;;S,;_ "VQNQG&?S/YUI**DC.,G%GKO[6G MC NR:UXRN0[9%N M-I]W;YV/_CP'X5S$;>3:AO;-?MU&"IQC#^56^X_(-73<^LW?[]39\*Z7+K_B M"WLX(_.F9UBBC_O2,0 /S(%?MAX)\$0?"KX4:#X0T]@S6MJEJTP)(1F63Z MLQ8_C7Y2?L-^#W\$;%HS):6LKZI='T2!2ZY^LOE#_@5?K3KFLB3Q.;< M'Y+6(9'^TW/\L5^5<;8Y4E"BW:_Z_P"23/T_A?"7@Y16WZ?\&PGA_P /QV_B M)) O%K#\OU/&?U-=I7.^$KH7TFHS YVRB/\ (9_K715\+EM.G3H7IK1MO]/R M1]5C9SG5M/=)(*X'X]>/_P#A5_P>\5^)4(%S96+_ &;=T\]_DB_#>R_AFN^K MYA_X*)ZL^G_L[RVZG'VW4[:!O<#<^/\ QRO6BKM(\^6B/RXFF>XF>65VDDD8 MLS, P%Z_J6F9I23_WWC\*Z:CM$YZ:NSV&BBBN0Z0H MHK)\6^((O"GA76-:GQY6GVDMTP/<(A;'Z4 ?D1^UEXF_X2S]HCQS>!_,2+4& MLT.<\0@1?S0UVG["/B3PGX*^,%WXA\6ZW9:+;V>G2):R7DFT-+(57Y??9O\ MSKYWU"^GU2_N;VYD,MS<2M-+(>K,Q))_,FH*[N72QQWUN?LC_P -6?"'_HH. MB_\ ?_\ ^M1_PU9\(?\ HH.B_P#?_P#^M7XW4Z&%[B9(HUW2.P55' V;'\3+&H M9OJ6R?QKY-_X*>>,!:>$?!WAF-_WE]>2W\JCJ$B0(N?8F4_]\UC%7D:R=HGY MY5^P7['O@W_A!_V<_!MFZ[;BZM3J,WJ6G8R#/N%95_"OQ]KU^S_:Y^+VG:?! M96OC>]@M8(UABCCAA 1%& !\G8"NF<7)61A&2B[L_7K7M>T[POH]WJNKWL&G M:;:1F6>ZN7")&H[DFOQ[_:>^+D?QK^,FM>(K0,-+&VTL PP?(C&%8^A8[FQV MW8KE/&7Q6\8_$/'_ DOB74]:13N$=W \DA^5?Y^@-*,.35CE+FT1Z;^PW\/;OQS^T'H5S'"S6&A[ MM2NY?X4"@B,?4N5X]B>U?K17D/[-/[.^E_L\^"3IT$HO];O66;4M0Q@2N!@( M@[(O. >>23UP/4]6U.#1=*O=0NFV6UI"]Q*WHB*68_D#6$Y (?%NLV> MBV.EV4\MO+>/M5YW7R@H]]KN?PKQ/Q-KT_BCQ)JNLW7-SJ%U+=R\Y^9W+']3 M6;75R^[8YKZW/V1_X:L^$/\ T4'1?^__ /\ 6H_X:L^$/_10=%_[_P#_ -:O MQNH&3P.367LD:>T9^Z/A7Q;H_CC0X-8T'48-5TN :A MA4UI<****P-ALDB0QM)(P1%!9F8X ZDU^)?QD\=R M?$SXI>)_$TCLZZA>R21%NHB!VQC\$51^%?KA^T9KTGAKX$>.]0A ^6K\7:Z*2W9A4?0^F/V _A/%\1/C5'J]\F_3/#47V]E89$DY.V%3 M]#N?_MF!WK]4*^./^"97AI;+X6>)M<9,2W^K?9E;N8XHD(_\>D;\J^QZSJ.\ MBX*T0KS[]H2..;X%^/TE ,9T.\SG_KDU>@UXO^V/XFC\+_LV^-YV?:]U:+8Q MCNS3.L9 _!F/T!J([HM['X_U^F7_ 31+?\ "B]9ST&OS8_[\05^9M?J9_P3 MOT=]+_9U@N'7'V_4KFX'N 5CS_XY754^$YZ>YYY_P4\\7"V\,>#/#,;_ #W= MU-?RJ.H6-0B9]B9&_P"^:^!O#NCS>(/$&F:5;KOGOKJ*VC4=V=PH'YFOI#_@ MHGXF.N?M!/IX?='I&G06VW/1FS*?_1@KYN\/Z]?^%] ZQ=XP)KV=I6 ] 6/ ^E9JD^IHZG8A\2: MY/XH\0ZGK%U@7-_ PXSU( MK]7OAS\/](^%O@O2_#&AP>3IUA%Y:YQND;JSL>[,223[U52=E9$PC=W9^#WB M.X-YK^IS?W[F0C_OHXJO='$<:?C6IX\TEM!\<>)--9=K6>I7-N5]-DK+_2L> MX;=+] !7[C&7-&ZZGY0X 4K8Z>9,G_Q MNOM+^TWO-?UR[SE9+UT3_=3@5\I?\$H(U76?B-/C+K;6:Y]MTI_I7TMX?F+: M?O;[SR.Y^I:OYK\1J\EF=*G?N_N45_[ M5&1R<\MHM]OR;1>9 MQY<947F%?)O_ 4IC9O@3I9 R%UR$M]/)F'\S7UE7@W[;W@N?QI^SGXE2UB, MUSIOEZDJ*.=L39D/X(7/X5[T?B1Y,MF?DA7[-_LRZI#K'[/OP_N8"&3^Q[>( M[>S1H$8?@RD?A7XR5]Z?\$\_VBM,TW2G^&?B"]6SE$[3Z--.P$;[SEX,GHVX MEE'?GPCNS2R* MK ?\ WG\*]GL-4L]569K*ZANUAE:&1H9 X21?O*<=",\BOBW_@I]XF\CPCX, M\/*^/M-]+?.N>OEQ[%_]&FKBKR1,GHS\\Z_3O]F?]E7X=:S\"_"&J>)/"-CJ MFKZA9B\EN;@-O99"63H?[I6OS3\/Z--XBU[3=*MQFXOKF.VCP,_,[!1_.OW, MT72;;P_H]AI=FGEV=E;QVT*?W410JC\@*VJNUK&--7U/+?\ AD7X._\ 0@Z7 M^3__ !52VO[)WPBL[F&XA\":7'-"XD1@'X8'(/WO6O6J*Y^9]S>R$Z<#I7Y> M_P#!1CQ.=:^/RZ:'W)I&FP0;<]&?,I_1UK]0B<#)X%?BI\>O%[^//C/XSUUG M\Q+K5)Q"W_3%&*1#\$5:UI+6YG4V-[]E?X8Z?\7?C=H/AW6('N='D$LUY$CL MA:-(V.-RD$?-MZ&O>_VM/V)/#/PE^'-UXQ\(7>J-]EN8EN;&\E26-(7)4LI" MALABG4G@FH?^"9'@]M0^(7BOQ,ZYBTW3TLT)_P">DS[LCZ+"W_?5??/Q \'6 M?Q"\#Z[X:OQFTU2SDM7('*[E(##W4X(]P*J4VI$QBG$_$;0=:G\.ZQ::E;1V M\TUM()%CNH$FB;'9D8$,#Z$5^PO[,GQ*TSXK?!S1==TW3[+1V.^WN].L$"16 MTZ'#*JCH"-K#V85^/.O:+<^'-)/$?@6ZEVKJ$0U&R#'@RQX611[E"K?2,U=175R:;L['Z%UY#^UMXG'A/\ M9U\<7N_8\EC]C3GJTS+%C_Q^O7J^-O\ @IIXL;3_ (8^&O#\4FUM2U,W$JC^ M*.&,\'VW2*?^ US15Y(WD[)GYP5^EW[*?[+?P]\0? ?POJ_B?PE9:KJ^H1R7 M4ESZA3/=O)9L?DIK]8:_#'P5XLOO ?B[1 M_$6F/Y=_IEU'=1'L2K [3[$<$>A-?LM\'OB_X?\ C5X+L_$&@7:2B1%%U:9_ M>VDI'S1R#L0<\]"!D9%.JM;BIO2QW%%%5[S4+735B:[N8K9995AC,SA=\C'" MH,]6)X ZFL#8\?\ VR=W_#-/CG;U^R)GZ>:F:_'^OVK^/7A6?QM\&/&FB6L9 MFN[O2YU@C Y>0(611]6 'XU^*E=-+8YZFY^IO_!.YXV_9QM0A!9=4N@^/[V5 M//X$5]-U\"_\$T_BQ8V*Z_X O[N.WN;J<:EIR2-CS6V!)47/5L(C8] Q[&OO MJL9Z29K%^Z%?"O\ P4S^)EO'I?AOP':SA[J24ZI>QJ?N( 4B!^I,AQ_L^XKZ MJ^-/QL\.? WP?<:YKUTHEVL+.P5OWUW*!PB#ZXRW0#DU^/\ \3?B)JOQ6\=: MOXIUEU-]J,QD,<>=D2=$C7/.U5 49YXYJZ<;NY-26ECF[>WDN[B*"%#)-(P1 M$4 *K>XETS3K>&*!K>=HF6>1F.X$=<+&>""/ MF'%?+\DC22,['+, MOI7EGP@^)C?"GQI::V=&TW7[5"%GL-3MDE21,Y^4L"48=0P_'(R*_37]N#X= MM\0OV?-<,$/G7VBE=6@ &3B,'S,?]LV?\J_)2E!\T=0DN5Z'[K^'-6LM>\/Z M;J6G%387EM'/!M \ME!7@>QK1KYA_X)\_$U_''P/31+J7S+_P -SFRR3EC MV7B)^@+(/9!7T]7+)6=CI3NKGXE_M@>%W\)?M*>/[%T*+)J+7:9'59@)0?\ MQ^O'B /+:';'?0G2KMU'!D3<\1/N5+CZ(/2O@JOV; M*ZZQIS7:WS6A^;8ZC['$SCY_GJ?>G_ 2CO%_X2CXA660'EL;60>O#N#_Z M$*^EM%S'8[#]Y)'4_G7Q?_P3&\41Z-^T- GX-_P#R1-X&U9=%^(T1D.V&[_=,?=AQ_P"/ 5[Y7R_KFZ&ZMKJ,[74XW>A! MR*^B?">O1^)?#]G?Q_>D3$B_W7'##\Z\SA:LJF =*^L)27W^\O\ TK\#MSVD MX8OG_F2?W:?H:]17-O%>6\L$R++#*A1T89#*1@@_A4M%?8'SQ^0O[5/[.FI? M 7QY<+%#)/X5U"1I=-O0AVJI)/DN>@=>GN #Z@>(U^Z'BWP?HWCS0+K1-?TV M#5=+NEVRVUPNY3W!'H0>01R*^.OB-_P3,TC4KZ2[\%^)Y='B?)_L_4XO/1#Z M+(I# >Q#'WKIC45K,YY4WT/D_P ,_M9?%KPCI\=E8>-=0-M&H5$NMMQM Z & M0$X_&H/%7[4GQ5\96 &V<6ZL#U!\L#(]J]N/_!,OQ[YF!XD MT$I_>S+G\ME=UX%_X)BVT%Y%/XO\8/=6RG+6>D6_EE_;S7)P/HOXBJYH;BY9 MGI__ 3KF,G[.<())V:K=+R?]P_UKY;_ ."C7C$>(/CS%I$;YAT/38;=E'_/ M60F5C_WR\8_X#7Z-?#GX:^'?A1X9BT#PQIR:;IL;F0QJ2S.Y !=F/+,0!R?0 M5\V?%+_@GU9_%/X@ZYXKO/'5W:SZI<& 2VN87$D4T+E'1@ MX_\ BZ^U/^'76D_]%!O/_!8G_P Z;;&6^N8)M3 MG='6.-F4,I;!!?8"#ZU[1_PZZTG_ **#>?\ @L3_ ..5ZO\ LY_L9Z;^SWXQ MO/$,/B2?7;B>S:T2.6T6$1@LK%LAVS]W%3*<;:#497U/9/BIXFC\&_#3Q5KL MCA%T_3+FY!/=EC8J/J3@?C7XA22--(\CG<[$L3ZDU^UGQL^&+?&+X;:KX1_M M:31(M1\L2W<4(E8(LBN5VDCKM Z]#7RK_P .NM)_Z*#>?^"Q/_CM33DHK4J< M7+8[+_@FWX9_LGX(:AJS)M?5M4D8-W*1JJ#\,A_UKZRKC?@_\-+/X/\ PWT3 MPA83M=V^FQ,OVAT"-*[.SNY )QEF)QFNRK*3N[FD596/RP_X*!?#5/ _QUGU M>UB\NQ\1P+?@ 8 F'R3 ?4@.?=S7C/P;^(4GPK^*'AOQ2@=H].O$DGCC^\\) M.V11[E"PK]4OVD_V:]*_:.T+2+*]U*31KW3+AIH+Z& 2ML9&5)'!(0YS_ M*^?O^'76D_\ 10;S_P %B?\ QRMXS7+9F,H.]T?;ME>P:E9P7=K*L]M/&LL4 MJ'(=6&01[$&OS;_X*6>+EU;XO:'H,4FY-(TM7E7^[+,[,1_WPL9_&OT$^&7@ MV;X>^ =#\-3ZH^LOI=N+87TD0C:1%)"94$XPN!U[9KYT^,'[ EI\7_B1K?B^ M]\<75G/J4BO]G73U<1*J*BJ&,@S@*.U90:C*[-))M:'YFVUS+9W$5Q;RO!/$ MX>.6-BK(P.001T(/>NL_X7+X_P#^AY\2?^#>X_\ BZ^U/^'76D_]%!O/_!8G M_P Z\8^(;JQ^U_:KF*75)V1XH5:5E8%\$-LVX_P!JO?/^ M'76D_P#10;S_ ,%B?_'*]/\ V>?V)],^ /CR3Q/%XFN- V\ >VY5S7NU% #_'7B'X?ZI_:7AO6;S1;W&TS6 *_6?XW_LI>!/CLSWFKV< MFGZ]LV+K&GD).<#"AP00X'N,XX!%?*.O?\$P_$MO<-_8_C+3+R#/R_;+>2%_ MQ"[A74JD7N<[@UL>,']M;XSRO^$TN,8QN^SP[OSV54^%OQ+\4?$#]H;X;W MGB?7[_6I8_$-AL-[.SK'FX3.U>B_@!7L^F_\$Q_& G:DY0 M2T&HR>Y]-5^37[9G[/M[\&OB7>:E:V^[PKK !O1@ JD>A M _66L?Q;X1T;QWX?N]$U_3H-4TJZ7;+;7"Y4\Y!]B#@@CD$5A&7*S64>9'X: MV5]<:;>0W=I/+:W4+B2*:%RCHP.0RL.00>XKV.R_;*^,=C8BTC\;WCQJ-H>: M.*23_OME)_6OJ#XC_P#!,S2M1OY;KP5XGDTB%R3_ &?J<1G1#Z+(I# >Q!/O M7G/_ [+\>^=M/B30?+_ +^9<_ELKHYX/ PXKJO@G\#?$WQU\5PZ/H%JPMU8&\U&13Y%I'W9CW/HH MY/ZU]D?#G_@F9HVFWL=UXT\3S:Q&F#]@TR+[/&Q]&D8EB/8!3[U]@>"_ ^@_ M#O0(-$\.:7;Z1ID.2MO;I@%CU9CU9CCDGDU,JB7PC5-O AZ?<>(YM!MM-FDG*PVHF\YV4*I.67 M&T!O^^JPB_>NS:2TLC\?Z_:/]G;P>G@/X'>"=%5/+DATR&69<8_?2#S9/_'W M:OF:T_X)@:/;W4$K^/;R5(W5FC_LU!N .2,^9WK[:MX$M;>*&,;8XU"*/0 8 M%:5)*6Q$(N.XEU;1WEM+;S()(94,;HPR&4C!!_"OQ.^,G@*?X8_%+Q-X8FC: M,:?>R1Q;OXH2=T3?0HRG\:_;:OFS]H;]B?2/C[XXB\3/XBGT"[^RI;3)#:+, M)MI.UB2RX.#C\!2IRY7J.<>9:'R%_P $_OB8_@?XZ0:/--LTWQ)";&1"?E\X M?/"WUR&4?]=#7ZH5\3Z/_P $T;7P_J]CJFG?$B^M=0LITN;>=-,3,TNX)+6[MY&AF@F4J\;J<,K M]"""*_H0K\N?^"DG[/;>!O'D?Q%TB!O[#\12;+]57Y;>] /S>PD49_WE;U%? M9<-XY4YO"S>DM5Z_\']#YS.L*YQ5>/31^A\W? 'QR?AK\:O!GB4R>5%8ZE$9 MFSC]RQV2@^VQFK]8OC!&VB^,(+U>+;4K<%6'3S$ZC\BOYU^+W7BOU<^#7BZ7 M]H#]D/1=26?[5XE\,#[) 2!0#N[Y>(JWN:\;Q'RJ6.RY5Z:O*&OW:_ES M+U9ZO!..CA\=[&H[1GI]_P#P;/Y$NK:I]HLW ;YE^9?J*[KX*>.DT^^73[B4 M+97Q!C+'A)>F/QZ?7%>(+KPFC5U;AAFG^'=8"7TMB6V[OWL!S^8_K^%?@G#& M-6&QOL9/W:JM_P!O+X?ONUZM'[-Q#EDJF#]M!>]3U^3W^[1^ES[GHKSGX3_$ MA/$]FNF7\@&K0+PS<>>@[C_:'?\ /UKT:OUX_*PHHHH **** "BBB@ HHHH M**** "LS4O$%II>IZ7I\KYO-2D=((5ZD(I9V/^R!C)]64=Q5;QKXTT?X>^&; M_7]=O8['3;.,R222'D^BJ/XF)X"CDD@5XW^S7JVI?]?\ BQK$#6UO>%M* MT"R;.+:R1\NWNSN!N/JAQQQ0*^MCZ HHHH&%%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SGQ$\ Z/\ M4/!6K^%M>M_M.E:G 895_B7NKJ>S*0&![$"NCHJHR<)*479HF45).,MF?A7\ M=O@GKGP"^(E_X5UL&81GS;.^"%4O+ KQ7QSX=UCX M=^)+O0M;@\F]MSPPY25#]UU/<'_ZW6OY8XFR"KDN-E96BWIY/?\ X*_X!_5' M"6 M6X@_M#0K\"#4]/;D21Y^^H/&] 1W_S^?X/Y'Y[Q'D53)<3S07[J?PO MM_=?FOQ7S/K"BOEKP+^T-JOA1H[#6XWU33XSL+-Q<1#TR?O8]&Y]Z]]\(_$K MPYXXBSI6I12S 9:VD.R9?JIY_$<5]!:Q\DFF=11112&%%%% !115+5M:T_0+ M"6^U.]M]/LX5W27%U*L:*/4L2 * +M&O"\,UAX'@_X235,E/MLH*6<7N/XI/H,#WKXA M\6>-/&/QR\:13:I=7.NZU?2K!;6T8^52QPL<<8X4?3ZGUH,Y32V/8_$WC[Q? M^V]\8-+\-V2OIGAN.8R168;*6T QOGE(^\^WIV!(4=23^C?AGP[8^$?#VFZ+ MID"V^GZ?;I;01J.B* !^/')[FO)?V6?V=[7X$^#/]+6*X\4ZDJR:A=)SL[K" MA_NKGD]SD^F/;:0XIK5A1113+"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_CM^S[X2_:"\ M+'2/$MIBXBRUGJ5OA;BT?U4]P>ZG@_7!'IE%:4ZDZ,U4INS1$X1J1<)JZ9^. MGQ(^!7Q0_8J^(5AXIL7DEL+*ZW6'B*Q4^1*,_P"KF7^# D>,=-0?:(%(:>RE(ZCN\#D3L17T[J6FVFLV$]C?VL-[9S MJ4EM[A \ +OV%8/#'C)?'/P7\0/X \3PMYBV$@,NG3\Y:-ARR MHW=?F7T4=O=Q>)PN=X?V&/BE/92Z/R?;U6SUT/.P<<5DV(6)P$G9.]NJ]._H M]UIJ?,_Q$^&NO_"[7FTK7K,P2')AG3F*=0?O(W<>W4=ZZCX(_'"]^%.I?9+H M27OAFZD#7-HN"\+'K+%GOZKT;'8\U]B:+<2_%3PX/"WQ6\%?V1KA!1U7,]E. MP!_>VMROW20,[25<<]0,U\^?%;]C#7?#LDE]X/D;7].Y)LY"%NH_8=G'TP?8 MU^,8W(\9E%?V^#?,EVU?_P!LO0_H#+>* :)1;T=]$WWO]E^OR9[E> MZ'X2^+&AV^JPB#4+>X7=#J-FVV3W!8=P>"K#@C&*\M\3_ 6^T^3[1H.KI,5Y M$=UF*1?HZY!_(5X)X'^(GB?X,^(+B.W66WPVV]T>^5ECD/\ M*>5<=F'/U'% M?4/@OXT:!\2;=$LIOL>K%-TFEW! E!'4IVD7W'/J!7TV69W1QUJ<_=J=N_I_ MEN?"YYPOB _P ]GY;'&:?XX^+_ ,/U\N)KK4;5/^6 + M^!R6 ^A%:D/[9/BO2ODU3PC#,PZ[1+ ?U#5TVK76W=VK@]>(_&]TUQK^MWVKRDYS=SLX'T!.!^%0W*M-)M4%W;@*!DD^E>W_"7] MBGQQ\1[B"ZUF!O">AMAFGOHR+AU]$B/.3ZM@?7I6D>">%_"6L>.->M=& MT+3Y]3U*Y;;';VZ%C[D^@ Y)/ '6OTE_9>_91T[X)6*:UJ_EZEXRN(MLDR_- M%9J>L<61U[%N_08'7T7X1_ [PG\%M&%EX>L%6YZT75=2T1E.Y8]P MG1#_ +.<,/\ OJBBO/Q.!PN*UK4TWWZ_?N>Q@LVQV!]W#5G%=KZ?<]/P/%O' MGAOQ!\+YFM1XNN]4B7A?,C*$#CU=AW]*X"]\8:U*"'U&1A[JO^%%% 3O_0,M>_\ A?\ 83\.7&RXUGQ%J6H+G)BMXT@!]LG<:**^@DVMCY&, M4]SW3P/\$? _PY"-H/ARSM;A1_Q]2*99S[^8^6_(UW-%%9&H4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% 0% !1110 4444 %%%% '_V0$! end